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Abstract Besides its essential role in hemostasis, there is growing evidence that von Willebrand
factor (VWF) has an additional antitumor effect. To elucidate the clinical signiﬁcance of
this biological activity we conducted a retrospective study on cancers among Italian
patients with von Willebrand disease (VWD) on behalf of the Italian Association of
Haemophilia Centres (AICE). A questionnaire to collect demographic, clinical, and
treatment data of VWD patients with cancer was sent to all the 54 Italian Haemophilia
Treatment Centres (HTCs) members of AICE. Overall, 18 HTCs (33%) provided informa-
tion on 92 VWD patients (61 alive and 31 deceased) with 106 cancers collected during
the period 1981 to 2014. Of them, 19 (18%) were hematological cancers and 87 (82%)
were solid cancers. A total of 61% of patients had type 1, 36% type 2 (12% type 2A, 14%
type 2B, 9% type 2M, and 1% type 2N), and 3% type 3 VWD: this distribution was
signiﬁcantly different from that observed in the whole VWD population (79% type 1,
16% type 2 [8% type 2A, 4% type 2B, 2% type 2M, 2% type 2N], and 5% type 3; type 2 vs.
non-type 2: p < 0.001). Overall, VWD patients with cancer underwent 52 invasive and
72 surgical procedures, were treated with VWF/factor VIII (FVIII) concentrates in 77
cases, with desmopressin (DDAVP) alone in 24 cases and with DDAVP and VWF/FVIII
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von Willebrand factor (VWF), a large multimeric plasma
protein synthesized by endothelial cells andmegakaryocytes,
plays a key role in promoting platelet adhesion and aggrega-
tion and in protecting coagulation factor VIII (FVIII) from
proteolytic degradation.1–3 Besides its essential role in
hemostasis, there is an increasing evidence that VWF may
have an additional antitumor effect, mainly through its anti-
angiogenic and proapoptotic properties.4 Indeed, while the
antiangiogenic action is exerted mostly by a negative modu-
lation of vascular endothelial growth factor receptor-2-de-
pendent angiogenesis,5 some experimental in vitro and in
vivo studies have demonstrated a critical role of VWF in
reducing metastasis by inducing tumor cell death.6,7 With
this background, it is not surprising that several clinical
studies have analyzed the relationship between circulating
or tissue VWF levels and malignancies,8–15 but the interpre-
tation of their results is greatly hindered by the fact that VWF
levels may be altered during inﬂammation. It is, therefore,
often difﬁcult to establish exactly whether raised VWF levels
are causal or a consequence of the underlying cancer-associ-
ated inﬂammatory process. On the other hand, so far only few
studies, published exclusively as case reports,16–18 have
systematically analyzed the issue of cancer in patients with
congenital von Willebrand disease (VWD). Thus, on behalf of
the Italian Association of Haemophilia Centres (AICE), we
have conducted a study on cancer among Italian VWD
patients followed at the Haemophilia Treatment Centres
(HTCs) with the aim of shedding light on this still unclear
issue.
Patients and Methods
Study Design
This retrospective study was approved by the Institutional
Review Boards of AICE and by local ethical committees of
the hospitals of the participating HTCs and was proposed at
thebeginningof 2012 toallmemberHTCs. Theprimaryobjective
of the study was to describe the cases of cancer (type of
neoplasm, patients’ outcome, and type of treatment used) in
the Italian population of VWD patients. A secondary aimwas to
investigate the inﬂuence, if any, of this inherited hemorrhagic
disorder on the management and outcome of malignancies.
Another secondary objective of our studywas to assess whether
a correlation exists between the entityof theVWFdefect and the
dissemination of malignancy at presentation.
A questionnaire designed to collect information on
demographic, clinical, and therapeutic data of VWD
patients with cancer was sent to all Italian HTCs that are
members of AICE. All cases of conﬁrmed cancer in VWD
patients, alive or deceased and followed by the HTCs
participating in the survey, were included. No restriction
of period of inclusion was required. For each case, the
following information was recorded: demographic data
(date of birth, age at death, and cause of death), type and
severity of VWD, VWF ristocetin cofactor (VWF:RCo) levels,
type of mutation (if known), presence of blood-borne viral
infections and their complications (i.e., chronic hepatitis B,
chronic hepatitis C, liver cirrhosis, hepatocellular carcino-
ma, human immunodeﬁciency virus [HIV] and acquired
immunodeﬁciency syndrome, response to antiviral treat-
ment for hepatitis C virus [HCV] or HIV), concomitant
diseases, and therapeutic data (type of VWF/FVIII concen-
trate, desmopressin [DDAVP, Kedrion Biopharma, Castel-
vecchio Pascoli, Italy] usage, treatment regimen, and mean
annual consumption). In addition, information was also
collected on the type and stage of cancer, the date of
diagnosis, the date and type of metastases, data on malig-
nancy management (invasive/surgical procedures, factor-
deﬁcient replacement therapy and bleeding complications
at presentation and during treatment, type of chemother-
apy or radiotherapy), occurrence of thrombocytopenia
(platelet count < 50  109/L), response to treatment, can-
cer progression or recurrence, outcome (alive or deceased)
and the period of follow-up. All patients had regular follow-
up visits at the HTC. We also collected information on
whether VWD had inﬂuenced the choice and availability
of cancer treatment modalities, patients’ participation in
experimental protocols, and completion of therapy or
whether a reduction of the doses of chemotherapy had
been necessary.
Statistical Analysis
All patients enrolled in the study were included in the
descriptive statistical analysis. Descriptive analyses of the
datawere performed using summary statistics for categorical
and quantitative data. The null hypothesis of a uniform
distribution of the frequencies between different groups
was analyzed by means of a Pearson chi-square test. Addi-
tionally, multivariable logistic analysis was performed and
results are presented as odds ratios (OR) and corresponding
95% conﬁdence intervals (CI).
Results
Total 18 of the 54 (33%) Italian HTCs that are members of
AICE agreed to participate in the study and provided
concentrates in 7 cases. Hemorrhagic complications were observed only rarely (2% of
invasive procedures and radiotherapy and 6% of surgical interventions). The data
collected by this survey document that a substantial number of cancers are recorded
among VWD patients and that these patients are safely managed by HTC physicians
through a multidisciplinary approach.
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information on 92 VWD patients (61 alive and 31 deceased
at the end of survey) who developed 106 cancers during the
period from January 1981 to June 2014. This cohort corre-
sponded to 6% (92/1,465) of the VWD population followed
by the enrolled HTCs, which represented 63% (1,465/2,317)
of the whole Italian population of people with
VWD. ►Table 1 summarizes the characteristics of the
VWD patients with cancer (number of patients alive and
deceased, median age at diagnosis of cancer and death, HCV
and HIV status) enrolled during the study period (1981–
2014). The median age of patients at cancer diagnosis was
58 years (range, 21–85 years), while the median age at death
was 68 years (range, 21–84 years). In the majority of cases
(24/31, 77%) the cause of death was cancer progression.
Other causes of death were bleeding and infectious compli-
cations, which accounted for 10% (3/31) and 13% (4/31) of
deaths, respectively. A total of 56 patients (61%) had type 1,
33 (36%) had type 2 (12% type 2A, 14% type 2B, 9% type 2M,
and 1% type 2N), and 3 (3%) had type 3 VWD. Among type 1
VWD patients, nine (16%) had type Vicenza variant VWD.
Interestingly, this distribution of VWD type in cancer pa-
tients was quite different from that observed in the whole
VWDpopulation followed at the 18 HTCs participating in the
study (79% type 1 [including also Vicenza variant], 16% type
2 [8% type 2A, 4% type 2B, 2% type 2M, 2% type 2N], and 5%
type 3; type 2 versus non-type 2 distribution between
cancer group and whole VWD population: p < 0.001; OR
2.91; 95% CI: 1.79–4.64). Concomitant viral infections were
observed in 15 (16%) patients (13 HCV, 1 HIV, 1 HIV/
HCV). ►Table 2 shows the number, types, and diffusion of
cancers according to patients’ VWD type and viral infection
status. Solid cancers accounted for the great majority (82%)
of the cases, while the remaining cases (18%) were hemato-
logical cancers. All six cases of hepatocellular carcinoma
recorded during the study period occurred in HCV-infected
VWD patients, as did 30% (3/10) of the cases of non-Hodgkin
lymphoma. Notably, the rate of HCV infections was higher in
patients with the more severe forms of VWD (2/3 [67%] in
type 3 VWD vs. 12/89 [13%] in non-type 3 VWD). No
difference in the distribution of VWD type was observed
between patients with solid tumors (61% type 1, 37% type 2
[13% type 2A, 12% type 2B, 9% type 2M, 3% type 2N] and 2%
type 3) and hematological cancers (58% type 1, 37% type 2
[11% type 2A, 21% type 2B, 5% type 2M] and 5% type 3). A
total of 13 patients had more than one cancer (12 had
two cancers and 1 had three cancers) with the following
distribution of VWD type: 8 type 1 (7%) and 5 type 2 (5%)
(3 type 2A, 1 type 2B, 1 type 2N). The patient suffering from
three cancers had a type 2N VWD. A total of 23 (25%) of the
94 cancers evaluable had metastasized before being diag-
nosed (15 type 1 [16%], 8 type 2 [8%] [5 type 2A, 2 type 2B, 1
type 2M]). No statistically signiﬁcant difference was ob-
served between median basal plasma VWF:RCo levels in
cancer patients with andwithout metastasis at presentation
(VWF:RCo levels: 20 IU/dL [range, 6–49 IU/dL] vs. 19 IU/dL
[range 1–48 IU/dL]; p ¼ nonsigniﬁcant).
►Table 3 shows the treatment characteristics of the
VWD patients with cancer enrolled in the study. Overall, Ta
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patients underwent 52 invasive and 72 surgical procedures,
were treated with VWF/FVIII concentrates in 77 cases, with
DDAVP alone in 24 cases and with DDAVP and VWF/FVIII
concentrates in 7 cases. The median dose of VWF/FVIII
concentrate and DDAVP administered was 45 IU/kg of
VWF:RCo (range, 20–66 IU/kg) and 0.3 µg/kg, respectively.
The median duration of treatment was 2 days (range, 1–6
days) for invasive procedures and 9 days (range, 1–39 days)
for surgical interventions. Hemorrhagic complications
were observed only rarely (2% [1/52] of invasive procedures
and 6% [4/72] of surgical interventions) and all but one (4/5,
80%) occurred in VWD type 1 patients not receiving anti-
hemorrhagic prophylaxis (median basal VWF:RCo levels:
27 IU/dL, range, 24–30 IU/dL). A total of 46% (37/81) and 31%
(22/71) of evaluable patients underwent chemotherapy
and radiotherapy, respectively, with no antihemorrhagic
prophylaxis. Hemorrhagic complications occurred in two
patients (9%) following radiotherapy. Eight of the 68 evalu-
able patients (12%) developed thrombocytopenia (platelet
count < 50  109/L), which was in all cases associated with
chemotherapy and/or radiotherapy. Finally, the recruiting
physicians reported that the underlying inherited hemor-
rhagic disorder did not inﬂuence the choice or completion
of the therapeutic protocol in any case nor had it resulted in
a reduction of chemotherapy dosages.
Discussion
The existence of a correlation between cancer and hemostasis
has been known for 150 years,19 with endogenous thrombin
being identiﬁed as a major contributor to tumor implantation,
seeding, and metastatization.20,21 Following observations from
in vitro studies,22,23 in the last two decades investigators have
analyzed this issue from the opposite side, that is, evaluating the
antineoplastic effect of antiplatelet and anticoagulant
agents.24–27 Besides these studies in pharmacologically anti-
coagulated patients, investigations have focused on naturally
anticoagulated patients, that is, hemophiliacs.28–31 Accordingly,
we previously conducted a retrospective survey among Italian
HTCs collecting 127 cases of cancer in 122 hemophiliacs over a
30-year period (1980–2010).32 In this study, 83% of patients
were infected by HCV and 22% of them were also coinfected by
HIV. A total of 43% of cancers were HCV-related, while 9% were
HIV-related. Virus-related cancers were more frequent and
nonvirus-related cancers less frequent in patients with severe
hemophilia than in those with mild/moderate forms
(p ¼ 0.0004). Notably, considering nonvirus-related cancers, a
low standardized mortality ratio (0.3) was found. Hemorrhagic
complications occurred more frequently in patients undergoing
chemotherapy (14%) or radiotherapy (19%). We therefore
decided to do the same survey in Italian VWD patients. To our
Table 2 Number, type, and diffusion of cancers according to the patients’ VWD type and viral infection status
Type of cancer Total
n (%)
VWD type
n (%)
Metastasisa
nQ1
Q1 (%)
HCVþ/HIVþ
n
Solid 87 (82) 53 type 1; 11 type 2A; 10 type 2B;
8 type 2M; 3 type 2N; 2 type 3
23 13/2
Urogenital tract 19 (22) 9 type 1; 2 type 2A; 3 type 2B; 3
type 2M; 2 type 2N
5 3/1
Gastrointestinal tract 17 (19) 14 type 1; 1 type 2A; 2 type 2B 4 2/0
Breast cancer 16 (18) 8 type 1; 3 type 2A; 1 type 2B; 3
type 2M; 1 type 3
4 0/0
Hepatocellular carcinoma 6 (7) 4 type 1; 1 type 2B; 1 type 2M 1 6/0
Respiratory system 9 (10) 5 type 1; 2 type 2A; 2 type 2B 5 0/0
Pancreas 3 (3) 3 type 1 1 0/0
Other cancersb 17 (19) 11 type 1; 3 type 2A; 1 type 2B; 1
type 2M; 1 type 3
3 2/1c
Hematological 19 (18) 11 type 1; 2 type 2A; 4 type 2B;
1 type 2M; 1 type 3
– 4/0
Non-Hodgkin lymphoma 10 (54) 6 type 1; 1 type 2A; 3 type 2B 3/0
Myeloproliferative disorders 5 (26) 2 type1; 1 type 2A; 1 type 2M; 1 type 3 0/0
Multiple myeloma 2 (10) 1 type 1; 1 type 2B 1/0
Chronic lymphocytic leukemia 1 (5) 1 type 1 0/0
Acute myeloid leukemia 1 (5) 1 type 1 0/0
Abbreviations: HCV, hepatitis C virus; HIV, human immunodeﬁciency virus; VWD, von Willebrand disease.
a94 cancers evaluable.
bOther cancers included skin (n ¼ 6), thyroid (n ¼ 4), meningioma (n ¼ 4), thymus (n ¼ 1), hypophysis (n ¼ 1) and bone (n ¼ 1).
cOne skin cancer occurred in a VWD patient with HIV/HCV coinfection.
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knowledge, this is theﬁrst study systematically investigating the
occurrence of cancers in a cohort of VWD patients. This issue is
however, in our opinion, potentially of great interest, also
considering the implication of VWF in angiogenesis and tumor
growth processes. Although we could not perform an epidemi-
ological analysis of our data due to the limited number of cancer
cases collected, some interesting information did emerge from
this study. First of all, the lower number of VWD cancer patients
infected by HCV and HIV infection (15% and 2%, respectively) as
compared with hemophilia patients reported in our previous
survey32 reﬂects on the one hand the generally lesser clinical
severity of VWD (with consequently less need for replacement
therapy) and on the other hand the widespread use of DDAVP
which prevented the exposure of a large number of VWD
patients to nonvirally inactivated VWF/FVIII concentrates which
were responsible for the transmission of blood-borne viruses
during the 1970s and the ﬁrst half of the 1980s.33 The results of
our study further support the association between HCV and
cancers: indeed, all cases of hepatocellular carcinoma occurred
in HCV-infected VWD patients and approximately 30% of the
cases of non-Hodgkin lymphomawere recorded inpatientswith
concomitant HCV infection, in keeping with current literature
data.34 The most striking ﬁnding of our study was, however, the
association between VWD type and cancer. Indeed, we found an
inversionof the ratio among thevariousVWDtypes,VWDtype2
being signiﬁcantly more frequent in our cohort of cancer VWD
patients than in the whole VWD population followed at the 18
HTCsparticipating in the study (33/92 [36%] vs. 236/1465 [16%]).
This ﬁnding is particularly intriguing considering that, of the
various different VWD types, VWD type 2 (especially subtype
2A) is that most frequently associated with angiodysplasia and
thus could be involved in the abnormal angiogenesis at the basis
of tumorigenesis.35,36 The hypothesis that cancer occurrence in
VWD patients might be related to a qualitative rather than a
quantitative VWF defect is further strengthened by the fact that
themedian basal VWF levels did not differ signiﬁcantly between
VWD patients with or without a more aggressive malignancy
(i.e., with metastasis) at presentation.
Notably, the fact that 80% of hemorrhagic complications
associated with invasive or surgical procedures occurred in
patients not receiving hemostatic treatment underlines the
importance of prophylactic antihemorrhagic therapy, also in
patients with milder VWD forms. Interestingly, although hem-
orrhagic complications occurred only rarely, 29% (2/7) of such
complications were observed in VWD cancer patients undergo-
ing radiotherapy, probably reﬂecting a synergistic effect
between treatment-related mucosal damage and the VWD-
associated tendency to mucosal bleeding. This ﬁnding suggests
that particular caution should be taken and antihemorrhagic
prophylaxis should be considered before starting radiotherapy
in suchpatients at increased riskofmucosal bleeding. Finally, the
ﬁnding that none of the cases of cancer metastasis at diagnosis
occurred in patients with VWD type 3 is potentially interesting
but needs to be conﬁrmed by larger studies.
In conclusion, the data collected by this survey document
that a substantial number of cancers are recorded among
VWD patients and that they can usually be managed safely by
physicians operating at HTCs through a multidisciplinary
approach. Further experimental and clinical studies are
needed to assess whether or not VWD predisposes to cancer.
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